Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > What a bunch of B.S....some people can't comprehend generic
View:
Post by subaru1i on Apr 03, 2024 6:38pm

What a bunch of B.S....some people can't comprehend generic

Epidiolex launch in the U.S.    If you don't like LABS, SELL IT ALL because at the gun club we are buying LABS including a financial advisor from CIBC that's a pretty good trap shooter as well.  

Buy a T-Bill and put it under your mattress.   Whiners will be put on ignore.
Comment by NoRiskNoReward on Apr 03, 2024 7:12pm
Generic versions Those competitors have submitted Abbreviated New Drug Applications (ANDAs) in order to “commercially market generic versions of GW’s cannabidiol oral solution drug product,” GW said in the lawsuit, noting some of the patents do not expire until September 2025, while the others are still in force until July 2027. Epidiolex received authorization for use in the treatment of two ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities